



Clinical Trial Information Sheet

Puma Biotechnology is committed to patients and care partners having the information you need to make informed decisions with your healthcare provider about your treatment options.

ABOUT THIS STUDY

This ALISCA-Breast1 study is an investigational Phase 2 clinical trial of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer focused on finding the optimal dose of alisertib in combination with endocrine therapy.

WHO QUALIFIES FOR THIS CLINICAL TRIAL?

The ALISCA-Breast 1 clinical trial is open to patients 18 years or older with pathologically confirmed recurrent or metastatic HR+, HER2-negative breast cancer who have received at least 2 prior lines of endocrine therapy including a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting, but who have not received chemotherapy in the recurrent or metastatic setting. Patients should talk to their doctor to discuss if they meet the study requirements.

WHAT'S INVOLVED?

- A screening period to do some tests and procedures to confirm eligibility
- A treatment period (total length depends on each patient)
- An end-of-treatment visit (when the patient stops taking alisertib)
- A safety follow-up visit (28 days after the last dose of alisertib)
- A long-term follow-up period
- Total length of participation in the clinical trial is approximately 26 months

WHO IS SPONSORING THIS STUDY?

This study is sponsored by Puma Biotechnology, a biopharmaceutical company focused on developing treatment options for different types of cancer.



The ALISCA-Breast1 alisertib trial is OPEN for enrollment!

For more information on the clinical trial, location of trial sites, and how to enroll,

- go to: www.clinicaltrials.gov Trial ID NCT06369285
- email: clinicaltrials@pumabiotechnology.com

For more information on the trial Sponsor,

- go to: www.PumaBiotechnology.com

This sheet is a high level snapshot of the trial. Please refer to the websites listed for more complete information.

Provided by Puma Biotechnology, Inc. All Rights Reserved 2026